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Indians undergoing socioeconomic and lifestyle transitions will
be maximally affected by epidemic of type 2 diabetes (T2D). We
conducted a two-stage genome-wide association study of T2D in
12,535 Indians, a less explored but high-risk group. We identiﬁed
a new type 2 diabetes–associated locus at 2q21, with the lead
signal being rs6723108 (odds ratio 1.31; P = 3.32 3 1029). Impu-
tation analysis reﬁned the signal to rs998451 (odds ratio 1.56;
P = 6.3 3 10212) within TMEM163 that encodes a probable ve-
sicular transporter in nerve terminals. TMEM163 variants also
showed association with decreased fasting plasma insulin and
homeostatic model assessment of insulin resistance, indicating
a plausible effect through impaired insulin secretion. The 2q21
region also harbors RAB3GAP1 and ACMSD; those are involved
in neurologic disorders. Forty-nine of 56 previously reported sig-
nals showed consistency in direction with similar effect sizes in
Indians and previous studies, and 25 of them were also associated
(P , 0.05). Known loci and the newly identiﬁed 2q21 locus alto-
gether explained 7.65% variance in the risk of T2D in Indians. Our
study suggests that common susceptibility variants for T2D are
largely the same across populations, but also reveals a popula-
tion-speciﬁc locus and provides further insights into genetic ar-
chitecture and etiology of T2D. Diabetes 62:977–986, 2013
Type 2 diabetes (T2D) has developed into a majorhealth problem, responsible for early morbiditiesand mortality that affects over a billion peopleworldwide (1). Developing countries such as
India will be maximally affected by the T2D epidemic, both
in terms of morbidity/mortality and socioeconomic loss in
the coming decade (1,2). India, with one-sixth of the
world’s population, typical risk phenotypes, and rapid so-
cioeconomic transitions, provides an important resource
for understanding the pathogenesis of T2D (1,3).
Genome-wide association studies (GWAS) and sub-
sequent meta-analyses have identiﬁed .56 susceptibility
loci for T2D that collectively explain ;10% of the disease
risk (4–8). Although GWAS have greatly improved our
understanding of the genetic basis of T2D, most of these
studies have been performed in Europeans (9), and the
studies involving South Asians are very limited (7,10). Inter-
population differences in allele frequencies and effect sizes
have yielded the discovery of new loci in different pop-
ulations (11). The relatively unexplored and high-risk
Indian population provides an opportunity for genetic
dissection of T2D and other metabolic disorders (3).
In this study, we performed a two-staged GWAS of T2D
involving a total of 12,535 Indians. The study involved
a genome scan of 2,465 subjects and replication of top
signals in two ethnic groups of India comprising 7,221
Indo-Europeans and 2,849 Dravidian subjects. These two
ethnic groups of India are genetically diverse due to dif-
ferent ancestral backgrounds (12); hence, data for these
two ethnic groups have been provided separately with the
primary focus on Indo-Europeans. Our study identiﬁed
a new T2D–associated locus on 2q21, with a lead signal at
rs6723108 near TMEM163. Imputation analysis and geno-
typing revealed a stronger signal on 2q21 at rs998451
within TMEM163. Further analysis suggested a probable
mechanism of inﬂuence of the TMEM163 variants on T2D
susceptibility through insulin secretion.
RESEARCH DESIGN AND METHODS
The present GWAS was performed in a two-stage study design (Fig. 1), in-
volving a total of 12,535 Indians comprising 6,738 T2D patients and 5,797
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nondiabetic control subjects. We performed a genome scan for 2,465 subjects
including 1,256 T2D patients and 1,209 nondiabetic control subjects of Indo-
European ethnicity in stage 1. Stage 2 comprised of replication of 708 single
nucleotide polymorphisms (SNPs; stage 1, P , 1.0 3 1023) not reported for
association with T2D by previous studies and 25 SNPs of previously reported
T2D-associated loci in 7,221 Indo-Europeans (3,937 T2D patients and 3,284
control subjects) and 2,849 Dravidians (1,545 T2D patients and 1,304 control
subjects).
All subjects of the current study are part of the Indian Diabetes Consortium
(INDICO) (13), a sample repository of two major ethnic groups of India,
namely Indo-European and Dravidian (14). Informed written consent was
obtained from all of the participants of the study. The study was approved by
the ethics committees of the participating institutes (13) and carried out in
accordance with the principles of the Helsinki Declaration.
Study participants
Stage 1. Consecutive T2D patients attending the outpatient Department of
Endocrinology clinic of All India Institute of Medical Sciences, New Delhi,
India, prior to September 2008, were enrolled as case subjects. T2D was di-
agnosed according to the World Health Organization criteria (i.e., fasting
plasma glucose level.126 mg/dL [7.0 mmol/L] or 2-h postglucose load of.200
mg/dL [11.1 mmol/L]) (15). Control group included subjects who met the fol-
lowing criteria: 1) $40 years of age; 2) HbA1c level #6.0%; 3) fasting plasma
glucose level ,110 mg/dL (6.1 mmol/L); 4) no family history of diabetes in
ﬁrst-degree relatives; and 5) urban dwellers. All of the control subjects were
collected from Diabetes Awareness Camps organized in various localities of
Delhi and nearby regions as described previously (13).
Stage 2. Stage 2 comprised subjects from two ethnic groups: Indo-European
and Dravidian. The ethnicity of the subject was deﬁned primarily on the basis of
geographical location of the recruitment along with their birth place and place
of origin of both the parents. Indo-European subjects were recruited from
northern part of the India that included mainly Delhi and neighboring states,
whereas Dravidian subjects were collected from Chennai, located in southern
part of India.
Indo-European case subjects included consecutive T2D patients recruited
from the outpatient departments of collaborating hospitals: All India Institute of
Medical Sciences (New Delhi), Guru Teg Bahadur Hospital (Delhi), and Sawai
Man Singh Hospital (Jaipur). T2D patients recruited from the All India Institute
of Medical Sciences (New Delhi) for stage 2 included only those subjects who
attended the clinic after September 2008. Subjects with self-reported diabetes
and/or taking medication for diabetes and newly diagnosed T2D patients were
also enrolled from Diabetes Awareness Camps. T2D was diagnosed according
to the World Health Organization criteria. Control subjects were recruited based
on the criteria as in stage 1, except that the fasting glucose level ,100 mg/dL
(5.6 mmol/L) was considered as the cutoff for subjects with missing information
about HbA1c levels. HbA1c levels were not available for 1,198 subjects in stage 2
of the study.
Subjects in the Dravidian group were recruited from an ongoing epidemi-
ology study, Chennai Urban Rural Epidemiological Study, on a representative
population (.20 years of age) of Chennai (16). Subjects with self-reported
diabetes taking drug treatment for diabetes or conﬁrmed by oral glucose tol-
erance test to have a 2-h postload plasma glucose level .200 mg/dL (11.1
mmol/L) were classiﬁed as T2D patients. Control subjects included randomly
selected subjects with a 2-h plasma glucose level ,140 mg/dL (7.8 mmol/L)
and fasting plasma glucose ,100 mg/dL (5.6 mmol/L). All recruited subjects
underwent anthropometric and clinical measurements. Height, weight, and
waist and hip circumferences were measured using standard methods as de-
scribed previously (13,16). Levels of glucose, HbA1c, insulin, C-peptide, total
cholesterol, triglycerides, HDL cholesterol, LDL cholesterol, and blood pres-
sure were measured as described previously (13,16). Homeostatic model as-
sessment of insulin resistance (HOMA-IR) was calculated as provided by
Matthews et al. (17). Anthropometric and clinical characteristics of the sub-
jects are provided in Supplementary Table 1.
Stage 1 genotyping and analysis. A genome scan was performed using
Illumina Human610-Quad BeadChips (Illumina Inc., San Diego, CA). Genotype
calls were assigned using the GenCall algorithm as implemented in Illumina
GenomeStudio (version 2010.3; Illumina Inc.). Stringent Quality Control (QC)
criteria for ﬁltering SNPs and samples for analyses were applied separately in
T2D case and control subjects (Supplementary Fig. 1). Samples with low call
rate (,95%), sex discrepancies, and cryptic relatedness (pi_hat .0.1875) were
removed. Cryptic relatedness was determined by identity-by-descent analysis
using PLINK v1.07 (http://pngu.mgh.harvard.edu/~purcell/plink) (18). SNPs
with minor allele frequency (MAF) ,0.01, either in case or control subjects,
were excluded (Supplementary Fig. 1). Further, from the SNPs with a MAF
0.01–0.05, those with a call rate ,99% and Hardy-Weinberg equilibrium (HWE)
of P , 5.7 3 1024 were excluded, whereas from SNPs with a MAF .0.05,
those with call rate ,95% and HWE of P , 1 3 1027 were removed.
FIG. 1. Study design.
GWAS IN INDIANS IDENTIFIES A NEW LOCUS FOR T2D
978 DIABETES, VOL. 62, MARCH 2013 diabetes.diabetesjournals.org
Principal component analysis was performed in stage 1 samples (without
inclusion of HapMap samples) to assess population structure and identify
outliers with 116,631 independent pruned SNPs using SMARTPCA as imple-
mented in EIGENSOFT version 3.0 (Supplementary Fig. 2). Pruning of
SNPs was carried out with successfully genotyped autosomal SNPs using the
–indep-pairwise option of PLINK v1.07, with a window size of 50 SNPs, step
size of 5, and r2 ,0.2. We also removed SNPs within regions of known high
linkage disequilibrium (LD) (19). The ﬁrst two principal components (PC1 and
PC2) had maximum contribution with eigenvalues of 8.41 and 4.33, re-
spectively. A total of 89 samples were identiﬁed as outliers that were removed
using the outlier removal option of SMARTPCA (s threshold of 6 with 5
iterations along ﬁrst 10 principal components). Principal component analysis
was also performed using our samples with reference samples from HapMap
Phase III populations CEU (Utah residents with Northern and Western Eu-
ropean ancestry from the Centre d’Etude du Polymorphisme Humain collec-
tion), GIH (Gujarati Indians in Houston, TX), YRI (Yoruban in Ibadan, Nigeria),
JPT (Japanese in Tokyo, Japan), and CHB (Han Chinese in Beijing, China)
using ﬁrst two eigenvectors.
Association of QC-passed SNPs with T2D was tested by logistic regression
analysis under a log-additive model adjusting for age, sex, and potential pop-
ulation stratiﬁcation using PLINK v1.07. Theﬁrst two principal components (PC1
and PC2) that accounted for the maximum variance were used as covariates to
adjust for residual population stratiﬁcation. Deviation between observed P
values for association and the expected P values under the null hypothesis was
investigated by constructing quantile–quantile plot. The 2log10 of P values
observed for the association of SNPs under the additive model adjusted for age,
sex, and ﬁrst two principal components was plotted against the theoretical
2log10 P values expected under the null hypothesis using STATA version 10.1
(Stata Corporation, College Station, TX). The genomic inﬂation factor (l) was
calculated from the average x2 statistics using PLINK v1.07.
Stage 2 genotyping and analysis. Genotyping of the selected SNPs in stage 2
was performed using the Illumina Golden Gate assay following the manufac-
turer’s instructions (http://support.illumina.com/documents/MyIllumina/2bbe5885-
34be-4e2e-b655-4848b7d3e3d7/GoldenGate_Genotyping_Assay_Guide_15004065_
B.pdf; Illumina Inc.). SNPs with a genotype conﬁdence score ,0.25, call fre-
quency ,0.90, GenTran score ,0.60, cluster separation score ,0.40, minor
allele frequency ,0.01, and HWE of P , 1.0 3 1025 were excluded. All of the
QC criteria for SNPs were applied separately in case and control subjects, and
only those SNPs that qualiﬁed QC both in case and control subjects were
taken forward for analysis. Samples with a ,0.90 call rate were also removed.
A total of 256 samples (;3%) were genotyped in duplicates, which showed
.99% concordance in genotype calls. Association of SNP T2D was assessed
separately in Indo-Europeans and Dravidians under the additive model using
logistic regression analysis adjusting for age and sex.
Results of stages 1 and 2 were combined by inverse variance method under
ﬁxed effect model using METAL (http://www.sph.umich.edu/csg/abecasis/
Metal/) (20). Association of the top four loci with quantitative clinical traits
including measures of adiposity, dysglycemia, and dyslipidemia was tested
using linear regression analysis under the additive model adjusted for age, sex,
and BMI as appropriate. Only nondiabetic control subjects from stages 1 and 2
were considered for association analysis with clinical traits. Pairwise LD be-
tween SNPs at the associated loci was determined using Haploview 4.0 soft-
ware (21). Haplotype association analyses were adjusted for age and sex and
assessed at 10,000 permutations using PLINK v1.07.
Imputation analysis. SNPs within a 2-Mb region around four lead signals were
imputed in ﬁnal post-QC genotype data using a 1000 Genomes Phase 1 (interim)
panel that consists of combined phased haplotypes of 1,094 individuals from
Africa, Asia, Europe, and America (build 37) using IMPUTE v2.1.2. (https://
mathgen.stats.ox.ac.uk/impute/impute_v2.html). Association was tested using
SNPTEST v2.2.0 (https://mathgen.stats.ox.ac.uk/genetics_software/snptest/
snptest.html) adjusting for age, sex, PC1, and PC2. Association analysis was
done for SNPs with a call rate .99%, threshold posterior probability of 0.90,
and proper_info .0.50.
Genotyping and analysis of the of the top imputed SNP. The SNP rs998451
that showed most signiﬁcant association after imputation was also conﬁrmed
by genotyping. Genotyping was performed in a total of 5,262 subjects (2,538
T2D patients and 2,724 nondiabetic control subjects) that included 2,036
subjects (1,087 T2D patients and 949 nondiabetic control subjects) of stage 1
and 3,226 subjects (1,451 T2D patients and 1,775 nondiabetic control subjects)
of stage 2. Genotyping was carried out by single-nucleotide extension of SNP-
speciﬁc probes using a SNaPshot ddNTP primer extension kit. The extended
probes were then electrophoresed on an ABI Prism 3100 genetic analyzer
(Applied Biosystems, Foster City, CA), and genotypes were determined using
GeneMapper Software v4.0. Call rate of the SNP was .99%, and genotypes did
not deviate from HWE (P. 0.05 in control subjects) in stage 1 or stage 2 study
populations. Association analyses were performed as mentioned above for
stage 1 and stage 2.
In silico replication. Associations of four top loci obtained in meta-analysis of
Indo-European samples were tested in Europeans by in silico replication using
GWAS phase data from the DIAGRAM+ study. DIAGRAM+ comprises GWAS
phase data of 8,130 individuals with T2D and 38,987 control subjects of Eu-
ropean descent with an effective sample size of 22,570 subjects (22). Meta-
analysis by combining summary statistics of results across the studies was
performed by inverse variance method under ﬁxed-effect model using METAL.
Calculation of phenotypic variance explained by selective SNPs. The
GCTA tool (23) was used for calculating the variance explained by combina-
tion of 56 SNPs from the 56 known loci of T2D and the SNP rs6723108 near
TMEM163 identiﬁed by the current study. The analysis was performed as-
suming a disease prevalence of 10% and adjusting for sex, age, PC1, and PC2.
Assuming a disease prevalence of 10% would mean the rest of the subjects
(90%) are control subjects and should represent the remaining liability dis-
tribution, which is not true in the current study, as control subjects were
deﬁned based on certain other criteria in addition to being unaffected with
T2D. Thus, results of this analysis are approximate.
Power calculation. Statistical power of the study was calculated for a range of
allele frequencies from 0.01 to 0.50, with odds ratios (ORs) ranging from 1.10 to
1.40, using Quanto software (http://hydra.usc.edu/gxe/), assuming a log-
additive model of inheritance and 10% prevalence of disease at a = 0.05
(Supplementary Fig. 3).
RESULTS
After stringent QC, a successfully genotyped dataset for
1,101 T2D patients and 1,027 control subjects at 536,420
autosomal SNPs was obtained in stage 1 (Supplementary
Fig. 1). The quantile–quantile plot showed good agreement
with null distribution (Supplementary Fig. 4). The genomic
control inﬂation factor (l) was 1.09. Consistent with pre-
vious reports, TCF7L2 was identiﬁed as the strongest
signal in Indians as well (OR 1.56; P = 5.01 3 10211) (Fig.
2). In stage 2, 708 SNPs (stage 1, P , 1.0 3 1023) not
reported for association with T2D by previous studies and
25 SNPs of previously reported T2D-associated loci were
genotyped. QC ﬁltering yielded data for 653 SNPs in 6,552
Indo-European subjects and 635 SNPs in 2,256 Dravidians.
We tested association of SNPs with T2D separately in
Indo-Europeans and Dravidians and combined the results
of two stages for Indo-European subjects by meta-analysis
using the ﬁxed-effect inverse variance method (20).
Combined analysis of Indo-European samples revea-
led strongest signal at rs7903146 of TCF7L2 (OR = 1.51
[95% CI 1.42–1.62; P = 1.2 3 10235) (Table 1). We identiﬁed
an unreported locus on 2q21 as a susceptibility region
for T2D at genome-wide signiﬁcance (P , 5.0 3 1028).
On 2q21, two SNPs: rs6723108 (OR 1.31 [95% CI 1.20–1.44];
P = 3.3 3 1029) and rs7570971 (OR 1.25 [95% CI 1.15–1.35];
P = 2.0 3 1028) reached genome-wide signiﬁcance (Table
1), whereas rs621341 (OR 1.25 [95% CI 1.14–1.36]; P = 6.9 3
1027) and rs624817 (OR 1.17 [95% CI 1.08–1.26]; P = 3.4 3
1025) showed suggestive association (Supplementary Table
2). These four SNPs were in moderate LD with each other
(r2 = 0.33–0.54) (Supplementary Fig. 5). Conditional analy-
sis led to substantial reduction in association of other SNPs
in the region when conditioned for rs6723108 (Fig. 3 and
Supplementary Table 3). Haplotype analysis suggested
a stronger signal within 2q21 region (OR 0.69; P = 4.0 3
10211 for TGC haplotype encompassing nonrisk alleles of
SNPs rs621341, rs6723108, and rs7570971, respectively)
(Supplementary Table 4). Hence, we performed in silico
ﬁne mapping by imputation within a 2-Mb region of
rs6723108 in stage 1 samples (Fig. 3) using the 1000
Genomes reference panel. The concordance rate of geno-
types pre- and postmasking 10% of the genotyped SNPs
was .98%. Imputation revealed a stronger signal at
rs998451 (OR 1.61; P = 9.2 3 1027) that lies in intron 2 of
TMEM163 (r2 = 0.84 with rs6723108) than any directly
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genotyped SNP of phase 1 (Supplementary Table 5). The
association results of imputation were also conﬁrmed
by genotyping rs998451 in a subset of samples of stage 1
(N = 2,036) and stage 2 (N = 3,226). The concordance rate
of imputed genotypes and directly genotyped genotypes
was 94%, suggesting successful imputation using the 1000
Genomes panel as a reference panel. The variant rs998451
was associated in both stage 1 (OR 1.43; P = 3.0 3 1024)
and stage 2 (OR 1.66; P = 2.7 3 1029) and crossed genome-
wide signiﬁcance (OR 1.56; P = 6.3 3 10212) after meta-
analysis (Table 1).
Replication analysis of 708 previously unreported SNPs
in the independent study population of Dravidians showed
association of 19 of them (P , 0.05) with consistent di-
rection with Indo-Europeans (Supplementary Table 6).
Among the top four loci in Indo-Europeans (P , 5.0 3
1026; Table 1), only rs1929752 (FLJ35379) was nominally
associated, but with opposite effect. SNPs rs10461617
(MAP3K1) and rs11165354 (TGFBR3) showed consistency
in direction but were not associated. The observed dis-
crepancies in association results might be due to differ-
ences in allele frequencies or effect sizes of these variants
between Indo-Europeans and Dravidians (Supplementary
Table 6); however, a larger study population of Dravidian
origin would be required to state anything conclusively.
We carried out in silico replication of top four loci—
TMEM163, MAP3K1, TGFBR31, and FLJ35379 in
DIAGRAM+—and performed meta-analysis (Supplemen-
tary Fig. 6). The SNP rs6723108 (TMEM163) had the same
direction of effect in DIAGRAM+; however, the association
was not statistically signiﬁcant. At the MAP3K1 locus
(rs10461617), suggestive association with consistent di-
rection was observed in DIAGRAM+. Nominal association
of rs11165354 of TGFBR3 in DIAGRAM+ was found
(P = 0.036), but there was inconsistency in direction of
effect. The observed differences in association results
might be due to differences in allele frequencies and LD
structures in Europeans and Indians.
Further, we investigated association of 56 T2D loci
identiﬁed by previous GWAS and assessed heterogeneity
in effect of the present and previous studies (Tables 2 and
3). A total of 49 loci showed consistency in direction of
association with similar effect sizes with previous reports
(P-heterogeneity .0.009, P value corrected for multiple
testing), and association for 25 of these loci was also
observed (P , 0.05). The seven loci HNF1B, DGKB-
TMEM195, SRR, KCNQ1, GLIS3, GCC1-PAX4, and PSMD6
were not consistent in direction, two of which (HNF1B
and SRR) also showed signiﬁcant heterogeneity of effect
even when our study was sufﬁciently powered (.98%) to
detect the associations. In Dravidians, association analysis
of 22 known loci that were genotyped in stage 2 (Supple-
mentary Table 7) showed that 17 loci have consistency in
direction and similar effect size, with 7 of these attaining
statistical signiﬁcance (P , 0.05).
To explore the possible functional mechanisms of the
identiﬁed loci, we performed association analysis with
quantitative traits. The risk allele of rs6723108 was asso-
ciated with decrease in fasting plasma insulin (b= 25.71
pmol/L; P = 3.73 1023) and HOMA-IR (b=20.21; P = 7.43
1023) in Indo-Europeans (Supplementary Table 8).
Similarly, rs998451 was also associated with decrease in
fasting plasma insulin (b= 25.54 pmol/L; P = 0.02) and
HOMA-IR (b= 20.20; P = 0.04). This suggests that
TMEM163 variants might modulate T2D susceptibility by
affecting insulin secretion. Previous studies have shown
that at this 2q21 region, rs6723108 and a variant in
RAB3GAP1 (rs6730157) are associated with waist cir-
cumference (24) (P = 6.2 3 1025) and total cholesterol
(P = 8.53 1028) (25), respectively. However, variants from
FIG. 2. Manhattan plot of the association P values for T2D. The 2log10 P values for association of directly genotyped SNPs are plotted as
a function of genomic position (National Center for Biotechnology Information Build 37). The P values were determined using logistic regression
adjusted for age, sex, PC1, and PC2 in stage 1 analysis. Each chromosome (Chr) has been represented with a unique color.
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this locus were not associated with these traits in our
study, which could be due to the small effect size of these
variants for these traits in the current study population or
lower power of the current study to detect them.
DISCUSSION
GWAS has enormously contributed to the identiﬁcation
of susceptibility genes for T2D and many other complex
disorders. The discovery of new susceptibility loci in
GWAS of different ethnic groups emphasizes the need
for conducting more GWAS in populations of diverse
ethnic groups. Our study also shows the potential of
identifying new signals through GWAS in population of
different ethnicity. In this study, we performed a GWAS
in Indians and identiﬁed a new signal for T2D on chro-
mosome 2q21.
The strongest signal on newly identiﬁed locus 2q21
mapped to TMEM163. The association of TMEM163 var-
iants (rs6723108 and rs998451) with reduced fasting
plasma insulin levels and HOMA-IR indicates that it might
modulate susceptibility to T2D by affecting insulin secre-
tion. Previously, rs6723108 has also been suggested to be
associated with waist circumference. These data indicate
the biological relevance of the identiﬁed locus with T2D.
TMEM163 encodes a synaptic vesicle membrane protein
with six putative transmembrane helices that may function
as a vesicular transporter. TMEM163 is expressed in
select brain regions and contained in subpopulations of
nerve terminals (26,27). This region also harbors
RAB3GAP1 and ACMSD, which are shown to be involved
in neurologic disorders (28). RAB3GAP1 encodes a cata-
lytic subunit of a Rab GTPase-activating protein involved in
regulated exocytosis of neurotransmitters and hormones.
Mutations in RAB3GAP1 are associated with neurode-
velopmental abnormalities known as Warburg micro syn-
drome (OMIM 600118). ACMSD codes for an enzyme
involved in picolinic and quinolinic acid homeostasis and
NAD biosynthesis (29,30). ACMSD activity and expression
have been shown to be elevated in streptozotocin-induced
diabetic rats and suppressed by insulin injection and is
suggested as a potential therapeutic avenue for diabetes
treatment (30). Thus, our results suggest the involvement
of neurologic component in the etiology of T2D, which
needs to be conﬁrmed through further investigations.
The signal on 2q21 observed in Indo-Europeans was
not detected in Dravidians and Europeans from
DIAGRAM+. The observed differences in association
results might be due to differences in allele frequencies
and LD structures or statistical power to detect the as-
sociation. In Dravidians, the minor allele frequency of
the index variant rs6723108 is very low (0.03) and differs
signiﬁcantly from that of Indo-Europeans, and hence, to
capture the association of this variant, if any, a larger
sample size is required. Thus, the statistical power of the
Dravidian study population might not be sufﬁcient to
detect the observed association in Indo-Europeans (Sup-
plementary Fig. 3). Among Europeans from DIAGRAM+
study, direction of effect was same as found in Indo-
Europeans, but the association could not reach statistical
signiﬁcance.
MAP3K1 was identiﬁed as a promising candidate
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FIG. 3. Regional plot of 2q21. Regional association plot depicting P value distribution of all genotyped and imputed SNPs in a 2-Mb region ﬂanking
the SNP rs6723108 (1 Mb each side) at chromosome 2q21. A: Stage 1 genotyped SNPs. B: Stage 1 genotyped and imputed SNPs. C: Stage 1 gen-
otyped and imputed SNPs conditioned for rs6723108. Strength of pairwise LD between all SNPs and rs6723108 has been color-coded and, based on
r2, computed from present study data (stage 1). Recombination rates were estimated from HapMap2 combined panel.
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transcription of insulin (32). We observed suggestive asso-
ciation at rs10461617 in the 59 ﬂank of MAP3K1. The
rs10461617 was also observed to have nominal association
with T2D in Dravidians and DIAGRAM+ with consistency in
direction of effect. Although the association of MAP3K1
variant could not reach genome-wide signiﬁcance, these
results and biological roles of MAP3K1 suggest it as an
important candidate for T2D.
Most of the previously reported T2D-associated loci
from earlier GWAS showed consistency in direction of
association with similar effect sizes in Indo-European
subjects of the present study, of which 25 were also as-
sociated at P, 0.05. Association at other known loci could
not be detected mainly due to the low power of the current
study to detect those associations, as most of these loci
were identiﬁed through meta-analysis of GWAS, including
large study populations. Only at loci PTPRD,HNF1B, THADA,
and SRR, we did not observe association even when our
study was sufﬁciently powered (.98%) to detect the pre-
viously reported effect sizes. The effect sizes at these loci
in our study population could be very small; thus, a larger
study population would be required to conﬁrm their as-
sociation status in our population. We also found consis-
tent results as in the recent GWAS in South Asians. Of the
six loci identiﬁed in the recent GWAS in South Asians (7),
HNF4A has been shown to be associated in our previous
study (33) involving study subjects from the current study
and was also associated in the current study (P = 0.004).
The loci HMG20A was also associated in the current study
(P = 0.02) while the other four loci (GRB14, ST6GAL1,
VPS26A, and AP3S2) showed consistency in direction and
effect size. All of the previously associated loci in Indo-
Europeans accounted for 7.17% of the variance in the risk
of T2D in our study population, which is similar to the
observations in previous studies (5 to 10%). The newly
identiﬁed 2q21 locus alone contributed 0.48% of the vari-
ance, and addition of 2q21 locus to the list increased the
total variance explained to 7.65%. Thus, our analysis pro-
vides further evidence for the belief that underlying dis-
ease mechanisms involving common variants are largely
similar among populations (11).
In conclusion, we identiﬁed a new locus associated with
T2D on the 2q21 region. The identiﬁed region 2q21 harbors
the genes TMEM163, RAB3GAP1, and ACMSDI, and in-
cidentally, all three are involved in neurologic processes,
suggesting a neurologic component in the etiology of T2D.
The ﬁndings provide new insights into the genetic archi-
tecture and pathophysiology of T2D; however, further
studies exploring the functional and clinical signiﬁcance of
the identiﬁed locus are warranted.
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